Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGCP Infrastructure Investments Regulatory News (GCP)

Share Price Information for GCP Infrastructure Investments (GCP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 76.60
Bid: 76.90
Ask: 77.70
Change: -0.60 (-0.78%)
Spread: 0.80 (1.04%)
Open: 76.60
High: 76.60
Low: 76.60
Prev. Close: 77.20
GCP Live PriceLast checked at -
GCP Infrastructure Investments is an Investment Trust

To provide shareholders with regular, sustainable, long-term dividend income and to preserve the capital value of its investments over the long term by generating exposure to infrastructure debt and/or similar assets.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results - Placing, Open Offer & C Share Offer

13 Mar 2014 11:40

RNS Number : 2367C
GCP Infrastructure Investments Ltd
13 March 2014
 



NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS OR INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

 

This announcement is not a prospectus. This announcement does not constitute or form part of, and should not be construed as, any offer or invitation to sell, issue, purchase or subscribe for, or any solicitation of any offer to sell, issue, purchase or subscribe for, any shares in the Company or securities in any other entity nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto. This announcement does not constitute a recommendation regarding any securities.

 

 

GCP Infrastructure Investments Limited (the "Company")

 

Result of Placing, Open Offer and Offer for Subscription of C Shares

 

13 March 2014

 

On 20 January 2014, the Company announced its intention to raise additional capital through a Placing, Open Offer and Offer for Subscription of C Shares of £0.01 each (the "C Shares") at an issue price of £1.00 per C Share (the "Issue") and the creation of a placing programme in relation to its Ordinary Shares of £0.01 each (the "Ordinary Shares") (the "Placing Programme"). 

 

The Company is pleased to announce today that the Issue has been significantly oversubscribed. Taking into account the lending opportunities available for investment in the near term, the Company will accept gross proceeds under the Issue of £80 million.

 

As the Issue was considerably oversubscribed, applications under the Issue will be scaled back in accordance with the terms and conditions set out in the Prospectus; however all applications made pursuant to Basic Entitlements under the Open Offer will be met in full.

 

A total of 80,000,000 C Shares will be issued (subject to Admission), of which 50,682,580 C Shares will be issued pursuant to the Open Offer and 29,317,420 C Shares will be issued pursuant to the Placing and the Offer for Subscription.

 

Application has been made for the C Shares to be admitted to the Official List and to trading on the London Stock Exchange's Main Market for listed securities ("Admission"). It is expected that Admission will become effective and dealings in the C Shares will commence on 18 March 2014.

 

Commenting on the fundraising, Ian Reeves CBE, Chairman, said:

"We are delighted with the support demonstrated by both existing shareholders and new investors for this equity raise. The strong demand for shares is a pleasing endorsement of our success in delivering the Company's investment objective to provide shareholders with regular, sustainable, long-term distributions and to preserve the capital value of its investment assets over the long term. The Board remains focused on this objective and as a result, the proceeds raised have been capped at £80 million in order to execute the specifically identified investment opportunities available to the Company in the near future."

Following Admission, the Company expects to have 355,058,164 Ordinary Shares and 80,000,000 C Shares in issue. The International Security Identification Number for the C Shares is JE00BJT12C24 and the TIDM is GCPI. The total number of voting rights of the Company will be 435,058,164 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

 

 

Contact details:

 

Gravis Capital Partners LLP

Stephen Ellis

Rollo Wright

 

 

+44 (0)20 7518 1495

+44 (0)20 7518 1493

Oriel Securities

Mark Bloomfield

Tunga Chigovanyika

Neil Winward

 

+44 (0)20 7710 7600

Cenkos Securities

Dion Di Miceli

Tom Scrivens

 

+44 (0)20 7397 1921

+44 (0)20 7397 1915

Buchanan

Charles Ryland

Sophie McNulty

 

 

+44 (0)20 7466 5000

Words and expressions that are defined in the prospectus published on 12 February 2014 by the Company shall have the same meanings where they are used in this announcement, except where the context requires otherwise.

 

This announcement is not for distribution, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Australia, Canada, Japan or South Africa. This announcement does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States, Australia, Canada, Japan or South Africa. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act" or the US Investment Company Act of 1940, as amended) and may not be offered or sold directly or indirectly into the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The securities referred to herein have not been registered under the applicable securities laws of Australia, Canada, Japan or South Africa and, subject to certain exceptions, may not be offered or sold within Australia, Canada, Japan or South Africa or to any national, resident or citizen of Australia, Canada, Japan or South Africa.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQKNDQDBKDKND
Date   Source Headline
8th Jun 20219:47 amRNSAdditional Listing and Total Voting Rights
28th May 20219:23 amRNSAdditional Listing
13th May 20217:00 amRNSScrip Share Reference Price
30th Apr 20217:00 amRNSInvestor Report at 31 March 2021
21st Apr 202111:06 amRNSDividend Declaration & Scrip Dividend Alternative
19th Apr 20217:00 amRNSNet Asset Value(s)
31st Mar 20217:00 amRNSTotal Voting Rights
30th Mar 20217:00 amRNSRevolving Credit Facility
22nd Mar 20211:08 pmRNSNew Directorship Notification
12th Mar 20211:29 pmRNSHolding(s) in Company
9th Mar 20214:26 pmRNSDirector/PDMR Shareholding
9th Mar 20219:08 amRNSAdditional Listing and Total Voting Rights
26th Feb 20219:39 amRNSAdditional Listing
11th Feb 20217:00 amRNSScrip Share Reference Price
10th Feb 202112:50 pmRNSDirectorate Change
10th Feb 202112:49 pmRNSResult of AGM
27th Jan 20217:00 amRNSInvestor Report at 31 December 2020
22nd Jan 202111:54 amRNSDividend Declaration & Scrip Dividend Alternative
18th Jan 20217:00 amRNSNet Asset Value(s)
11th Jan 202110:31 amRNSUpdate research from QuotedData
8th Jan 20219:00 amRNSNotice of AGM Circular
31st Dec 20207:00 amRNSTotal Voting Rights
17th Dec 20207:00 amRNSAnnual report and financial statements
7th Dec 202012:37 pmRNSDirector/PDMR Shareholding
7th Dec 20209:13 amRNSAdditional Listing and Total Voting Rights
4th Dec 20207:00 amRNSInvestment Adviser strategic partnership
27th Nov 20207:00 amRNSAdditional Listing
12th Nov 20207:00 amRNSScrip Share Reference Price
30th Oct 20207:00 amRNSInvestor Report as at 30 September 2020
23rd Oct 202011:42 amRNSDividend Declaration & Scrip Dividend Alternative
23rd Oct 202010:41 amRNSDividend Declaration & Script Dividend Alternative
16th Oct 20207:00 amRNSNet Asset Value(s)
12th Oct 20207:00 amRNSGreen Economy Mark
3rd Sep 202012:50 pmRNSDirector/PDMR Shareholding
28th Aug 20209:56 amRNSAdditional Listing and Total Voting Rights
21st Aug 202012:54 pmRNSAdditional Listing
6th Aug 20207:00 amRNSScrip Share Reference Price
30th Jul 20207:00 amRNSInvestor Report as at 30 June 2020
28th Jul 20201:19 pmRNSNotification of Major Holdings
23rd Jul 202010:42 amRNSDividend Declaration & Scrip Dividend Alternative
15th Jul 20207:00 amRNSNet Asset Value(s)
30th Jun 20207:00 amRNSTotal Voting Rights
10th Jun 20205:35 pmRNSDirector/PDMR Shareholding
10th Jun 202012:04 pmRNSAdditional Listing and Total Voting Rights
3rd Jun 20207:00 amRNSAdditional Listing
1st Jun 20201:48 pmRNSUpdate research from QuotedData
29th May 20207:00 amRNSHalf-yearly Report and Financial Statements 2020
15th May 20207:00 amRNSScrip Share Reference Price
1st May 20207:00 amRNSInvestor Report as at 31 March 2020
24th Apr 202011:16 amRNSDividend Declaration & Scrip Dividend Alternative

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.